# Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

> **NCT04235114** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Saskatchewan** · enrollment: 14 (estimated)

## Conditions studied

- Lung Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** 50 mg 89Zr-DFO-Nimotuzumab
- **DRUG:** 1 mg 89Zr-DFO-Nimotuzumab

## Key facts

- **NCT ID:** NCT04235114
- **Lead sponsor:** University of Saskatchewan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-01
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04235114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04235114, "Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04235114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*